Personalised health care is starting to move into clinical practice - and patients, health care providers and payers could all benefit.
After years of development, personalised health care is starting to move into clinical practice - and patients, healthcare providers and payers could all benefit. This conference highlights:
- Case studies - where, and in for what indications, has it been shown to work already?
- Modeling - What would be the public health impact be if scaled up across an entire country or the European Union?
- Management - How should health authorities adapt to maximise the benefit and minimise the cost?
- Investment - What companies, large and small, will be first to capitalise on this opportunity?
- International - How can EU coordination, and international collaboration, speed adoption?
The conference will draw on new research by Science|Business on the macroeconomic impact of personalised health care across the EU. It will provide policy input, networking and information-sharing for:
- Public health authorities and payers across the EU
- Biopharma, ICT, diagnostics and device companies, both small and large
- Investors and analysts
- Researchers in industry and academia
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
